Coagulation in hematological malignancies

Cancer Investigation

Volumn 27, Issue SUPPL. 1, 2009, Pages 7-16

  Falanga, Anna ^a   Vignoli, Alfonso ^a   Marchetti, Marina ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Coagulopathy; Hematological malignancies; Hypercoagulable state; Leukemia; Lymphoma; Multiple myeloma; Thromboprophylaxis; Thrombosis; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; ASPARAGINASE; DEXAMETHASONE; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PLACEBO; RETINOIC ACID; THALIDOMIDE; TRANEXAMIC ACID; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TUMOR CELL; VENOUS THROMBOEMBOLISM;

EID: 70349519220     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802656509     Document Type: Article

References (86)

1. Falanga, A.; Rickles, F.R. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007, 165-171
2. Falanga, A.; Marchetti, M. Thromboembolism in hematologic malignancies. In Cancer-Associated Thrombosis. A.A. Khorana and C.W. Francis (eds.). New York, NY: Informa Healthcare, 2008, 131-149.
3. White, R.H.; Chew, H.K.; Zhou, H.; Parikh-Patel, A.; Harris, D.; Harvey, D.; Wun, T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528693 adults. Arch Intern Med 2005, 165, 1782-1787.
4. Khorana, A.A.; Francis, C.W.; Culakova, E.; Lyman, G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005, 104, 2822-2829.
5. Khorana, A.A.; Francis, C.W.; Culakova, E.; Fisher, R.I.; Kuderer, N.M., Lyman, G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Onc 2006, 24, 484-490.
6. Falanga, A.; Marchetti, M. Oncology. In Practical Hemostasis and Thrombosis. O'Shaughnessy, M. Makris, and D. Lillicrap. (eds.) Chapter 20. Blackwell Publishing 2005, 190-200.
7. Palumbo, A.; Rajkumar, S.V.; Dimopoulos, M.A.; Richardson, P.G.; San Miguel, J.; Barlogie, B.; Harousseau, J.; Zonder, J.A.; Cavo, M.; Zangari, M.; Attal, M.; Belch, A.; Knop, S.; Joshua, D.; Sezer, O.; Ludwig, H.; Vesole, D.; Blad́e, J.; Kyle, R.; Westin, J.; Weber, D.; Bringhen, S.; Niesvizky, R.; Waage, A.; von Lilienfeld-Toal, M.; Lonial, S.; Morgan, G.J.; Orlowski, R.Z.; Shimizu, K.; Anderson, K.C.; Boccadoro, M.; Durie, B.G.; Sonneveld, P.; Hussein, M.A.; International Myeloma Working Group. Prevention of thalidomideand lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22, 414-423.
8. Cortelezzi, A.; Moia, M.; Falanga, A.; Pogliani, E.M.; Agnelli, G.; Bonizzoni, E.; Gussoni, G.; Barbui, T.; Mannucci, P.M. CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Brit J Hematol 2005, 129, 811-817.
9. Couban, S.; Goodyear, M.; Burnell, M.; Dolan, S.;Wasi, P.; Barnes, D.; Macleod, D.; Burton, E.; Andreou, P.; Anderson, D.R. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005, 23, 4063-4069.
10. Falanga, A.; Barbui, T.; Rickles, F.R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008, 34, 204-210.
11. Clarke, C.S.; Otridge, B.W.; Carney, D.N. Thromboembolism. A complication of weekly chemotherapy in the treatment of non- Hodgkin's lymphoma. Cancer 1990, 66, 2027-2030.
12. Ottinger, H.; Belka, C.; Kozole, G.; Engelhard, M.; Meusers, P.; Paar, D.; Metz, K.A.; Leder, L.D.; Cyrus, C.; Gnoth S.; et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995, 54, 186-194.
13. Mohren, M.; Markmann, I.; Jentsch-Ullrich, K.; Koenigsmann, M.; Lutze, G.; Franke, A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005, 92, 1349-1351.
14. Komrokji, R.S.; Uppal, N.P, Khorana, A.A.; Lyman, G.H.; Kaplan, K.L.; Fisher, R.I.; Francis, C.W. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006, 47, 1029-1033.
15. Goldschmidt, N.; Linetsky, E.; Shalom, E.; Varon, D.; Siegal, T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003, 98, 1239-1242.
16. Athale, U.H.; Nagel, K.; Khan, A.A.; Chan, A.K. Thromboembolism in children with lymphoma. Thromb Res 2008, 122, 459-465.
17. Ziegler, S.; Sperr,W.R.; Kn̈obl, P.; Lehr ,S.;Weltermann, A.; Jäger, U.; Valent, P.; Lechner, K. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005, 115, 59-64.
18. De Stefano, V.; Sorà, F.; Rossi, E.; Chiusolo, P.; Laurenti, L.; Fianchi, L.; Zini, G.; Pagano, L.; Sica, S.; Leone, G. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005, 3, 1985-1992.
19. Melillo, L.; Grandone, E.; Colaizzo, D.; Cappucci, F.; Valvano, M.R.; Cascavilla, N. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007, 117, 215-220.
20. Mohren, M.; Markmann, I.; Jentsch-Ullrich, K.; Koenigsmann, M.; Lutze, G.; Franke, A. Increased risk of venous thromboembolism in patients with acute leukemia. Br J Cancer 2006, 94, 200-202.
21. Caruso, V.; Iacoviello, L.; Di Castelnuovo, A.; Storti, S.; Donati, M.B. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a metaanalysis. J Thromb Haemost 2007, 5, 621-623.
22. Rodeghiero, F.; Avvisati, G.; Castaman, G.; Barbui, T.;Mandelli, M. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990, 75, 2112-2117.
23. Falanga, A.; Rickles, F.R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003, 16, 463-482.
24. de la Serna J.; Montesinos, P.; Vellenga, E.; Rayón, C.; Parody, R.; Léon, A.; Esteve, J.; Bergua, J.M.; Milone, G.; Deb́en, G.; Rivas, C.; Gonźalez, M.; Tormo, M.; Díaz-Mediavilla, J.; Gonźalez, J.D.; Negri, S.; Amutio, E.; Brunet, S.; Lowenberg, B.; Sanz, M.A. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111, 3395-3402.
25. Rickles, FR.; Falanga, A.; Montesinos, P.; Sanz, M.A.; Brenner, B.; Barbui, T. Bleeding and thrombosis in acute leukemia: What does the future of therapy look like? Thromb Res 2007, 120(Suppl. 2), S99-S106.
26. Priest, J.R.; Ramsay, N.K.; Steinherz, P.G.; Tubergen, D.G.; Cairo, M.S.; Sitarz, A.L.; Bishop, A.J.; White, L.; Trigg, M.E.; Levitt, C.J.; Cich, J.A.; Coccia, P.F. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982, 100, 984-989.
27. Pui, C.H.; Jackson, C.W.; Chesney, C.; Lyles, S.A.; Bowman,W.P.; Abromowitch, M.; Simone, J.V. Sequential changes in platelet function and coagulation in leukemic children treated with Lasparaginase, prednisone and vincristine. J Clin Oncol 1983, 1, 380-385.
28. Nowak-Göttl, U.; Wermes, C.; Junker, R.; Koch, H.G.; Schobess, R.; Fleischhack, G.; Schwabe D.; Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further thrombotic risk factors. Blood 1999, 93, 1595-1599.
29. Caruso, V.; Iacoviello, L.; Di Castelnuovo, A.; Storti, S.;Mariani, G.; de Gaetan, G.; Donati, M.B. Thrombotic complications in childhood acute lymphoblastic leukcemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006, 108, 2216-2222.
30. Annino, L.; Vegna, M.L.; Camera, A.; Specchia, G.; Visani G.; Fioritoni, G.; Ferrara, F.; Peta, A.; Ciolli, S.; Deplano, W.; Fabbiano, F.; Sica, S.; Di Raimondo, F.; Cascavilla, N.; Tabilio, A.; Leoni, P.; Invernizzi, R.; Baccarani, M.; Rotoli, B.; Amadori, S.; Mandelli, F.; GIMEMA Group. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99, 863-871.
31. Sarris, A.H.; Kempin, S.; Berman, E.; Michaeli, J.; Little, C.; Andreeff, M.; Gee, T.; Straus, D.; Gansbacher, B.; Filippa, D.; Glaser, B.; Clarkson, B. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992, 79, 1305-1310.
32. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341, 1565-1571.
33. Barlogie, B.; Tricot, G.; Anaissie, E.; Shaughnessy, J.; Rasmussen, E.; van Rhee, F.; Fassas, A.; Zangari, M.; Hollmig, K.; Pineda-Roman, M.; Lee, C.; Talamo, G.; Thertulien, R.; Kiwan, E.; Krishna, S.; Fox, M.; Crowley, J. Thalidomide and hematopoietic-celltranplantation for multiple myeloma. N Engl J Med 2006, 354, 1021-1030.
34. Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003, 21, 16-19.
35. Rajkumar, S.V.; Gertz, M.A.; Lacy, M.Q.; Dispenzieri, A.; Fonseca, R.; Geyer, S.M.; Iturria, N.; Kumar, S.; Lust, J.A.; Kyle, R.A.; Greipp, P.R.; Witzig, T.E. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17, 775-779.
36. Barlogie, B.; Desikan, R.; Eddlemon, P.; Spencer, T.; Zeldis, J.; Munshi, N.; Badros, A.; Zangari, M.; Anaissie, E.; Epstein, J.; Shaughnessy, J.; Ayers, D.; Spoon, D.; Tricot, G. Extended survival in advanced and refractory multiple myeloma after singleagent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98, 492-494.
37. Neben, K.; Moehler, T.; Benner, A.; Kraemer, A.; Egerer, G.; Ho, A.D.; Goldschmidt, H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002, 8, 3377-3382.
38. Schey, S.A.; Cavenagh, J.; Johnson, R.; Child, J.A.; Oakervee, H.; Jones, R.W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003, 27, 909-914.
39. Osman, K.; Comenzo, R.; Rajkumar, S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001, 344, 1951-1952.
40. Rajkumar, S.V.; Blood, E.; Vesole, D.; Fonseca, R.; Greipp, P.R.; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24, 431-436.
41. Cavo, M.; Zamagni, E.; Tosi, P.; Cellini, C.; Cangini, D.; Tacchetti, P.; Testoni, N.; Tonelli, M.; de Vivo, A.; Palareti, G.; Tura, S.; Baccarani, M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004, 89, 826-831.
42. Palumbo, A.; Bertola, A.; Falco, P.; Rosato, R.; Cavallo, F.; Giaccone, L.; Bringhen, S.; Musto, P.; Pregno, P.; Caravita, T.; Ciccone, G.; Boccadoro, M. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004, 5, 318-324.
43. Anagnostopoulos, A.; Weber, D.; Rankin, K.; Delasalle, K.; Alexanian, R.Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003, 121, 768-771.
44. Rus, C.; Bazzan, M.; Palumbo, A.; Bringhen S.; Boccadoro M. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004, 2, 2063-2065.
45. Zangari, M.; Anaissie, E.; Barlogie, B. Increased risk of deep vein thrombosis in patients withmultiplemyeloma receiving thalidomide and chemotherapy. Blood 2001, 98, 1614-1615.
46. Zangari, M.; Saghafifar, F.; Anaissie, E.; Badros, A.; Desikan, R.; Fassas, A.; Mehta, P.; Morris, C.; Toor, A.; Whitfield, D.; Siegel, E.; Barlogie, B.; Fink, L.; Tricot, G. Activated protein C in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002, 13, 187-192.
47. Dimopoulos, M.A.; Anagnostopoulos, A.; Terpos, E.; Repoussis, P.; Zomas, A.; Katodritou, E.; Kyrtsonis, M.C.; Delibasi, S.; Vassou, A.; Pouli, A.; Zervas, K.; Anagnostopoulos, N.; Maniatis, A.; Greek Myeloma Study Group. Primary treatmente with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006, 91, 252-254.
48. Zervas K.; Dimopoulos, M.A.; Hatzicharissi, E.; Anagnostopoulos, A.; Papaioannou, M.; Mitsouli, Ch.; Panagiotidis, P.; Korantzis, J.; Tzilianos, M.; Maniatis, A.; Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexhamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004, 15, 134-138.
49. Sidra, G.; Williams, C.D.; Russell, N.H.; Zaman, S.; Myers, B.; Byrne, J.L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006, 91, 862-863.
50. Baz, R.; Li, L.; Kottke-Marchant, K.; Srkalovic, G.; McGowan, B.; Yiannaki, E.; Kara, M.A.; Faiman, B.; Jawde, R.A.; Andresen, S.; Zeldis, J.; Hussein, M.A. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80, 1568-1574.
51. Offidani, M.; Corvatta, L.; Marconi, M.; Olivieri, A.; Catarini, M.; Mele, A.; Brunori, M.; Candela, M.; Malerba, L.; Capelli, D.; Montanari, M.; Leoni, P. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004, 5, 312-317.
52. Dimopoulos, M.A.; Hamilos, G.; Zomas, A.; Gika, D.; Efstathiou, E.; Grigoraki, V.; Poziopoulos,C.; Xilouri, I.; Zorzou, MP.; Anagnostopoulos, N.; Anagnostopoulos, A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for prviously treated patients with multiple myeloma. Hematol J 2004, 5, 112-117.
53. Garćýa-Sanz, R.; Gonźalez-Porras, JR.; Herńandez, JM.; Polo- Zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; Ĺopez, R.; Grande-Garćýa, C.; Alegre, A.; Vargas-Pab́on, M.; Gutíerrez, O.N.; Rodŕýguez, J.A.; San Miguel JF. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004, 18, 856-863.
54. Kropff, M.H.; Lang, N.; Bisping, G.; Domiń e, N.; Innig, G.; Hentrich, M.; Mitterer, M.; Südhoff, T.; Fenk, R.; Straka, C.; Heinecke, A.; Koch, O.M.; Ostermann, H.; Berdel, W.E.; Kienast, J. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003, 122, 607-616.
55. Suvannasankha, A.; Fausel, C.; Juliar, B.E.; Yiannoutsos, C.T.; Fisher, W.B.; Ansari, R.H.; Wood, L.L.; Smith, G.G.; Cripe, L.D.; Abonour, R. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier oncology group trial, HEM01-21. Oncologist 2007, 12, 99-106.
56. Zangari, M.; Barlogie, B.; Thertulien, R.; Jacobson, J.; Eddleman, P.; Fink, L.; Fassas, A.; Van Rhee, F.; Talamo, G.; Lee, C.K.; Tricot, G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003, 4, 32-35.
57. Urbauer, E.; Kaufmann, H.; Nosslinger, T.; N̈osslinger, T.; Raderer, M.; Drach, J. Thromboembolic events during treatment with thalidomide. Blood 2002, 99, 4247-4248.
58. Richardson, P.G.; Blood, E.; Mitsiades, C.S.; Jagannath, S.; Zeldenrust, S.R.; Alsina, M.; Schlossman, R.L.; Rajkumar, S.V.; Desikan, K.R.; Hideshima, T.; Munshi, N.C.; Kelly-Colson, K.; Doss, D.; McKenney, M.L.; Gorelik, S.; Warren, D.; Freeman, A.; Rich, R.;Wu, A.; Olesnyckyj, M.; Wride, K.; Dalton,W.S.; Zeldis, J.; Knight, R.;Weller, E.; Anderson, K.C. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108, 3458-3464.
59. Zonder, J.A.; Durie, B.G.M.; McCoy, J.; Crowley, J.; Hussein, M.A. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. ASH annual meeting. Blood 2005, 106, 3455.
60. Menon, S.P.; Rajkumar, S.V.; Lacy, M.; Falco, P.; Palumbo, A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008, 112, 1522-1528.
61. Rajkumar, S.V.; Jacobus, S.; Callander, N.; Fonseca, R.; Vesole, D.; Williams, M.; Abonour, R.; Siegel, S.; Greipp, P. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol 2007, 25(18 Suppl.), LBA8025.
62. Dimopoulos, M.; Spencer, A.; Attal, M.; Prince, H.M.; Harousseau, J.L.; Dmoszynska, A.; San Miguel, J.; Hellmann, A.; Facon, T.; Foà, R.; Corso, A.; Masliak, Z.; Olesnyckyj, M.; Yu, Z.; Patin, J.; Zeldis, J.B.; Knight, R.D.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357, 2123-2132.
63. Weber, D.M.; Chen, C.; Niesvizky, R.; Wang, M.; Belch, A.; Stadtmauer, E.A.; Siegel, D.; Borrello, I.; Rajkumar, S.V.; Chanan-Khan, A.A.; Lonial, S.; Yu ,Z.; Patin, J.; Olesnyckyj, M.; Zeldis, J.B.; Knight, R.D.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsedmultiplemyeloma in North America. N Engl J Med 2007, 357, 2133-2142.
64. Falanga, A.; Ofosu, F.A.; Delaini, F.; Oldani, E.; Dewar, L.; Lui, L.; Barbui, T. The hypercoagulable state in cancer: evidence for impaired thrombin inhibition. Blood Coag & Fibr 1994, 5, S19-S23.
65. Falanga, A.; Marchetti, M.; Vignoli, A.; Balducci, D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003, 1, 673-678.
66. De Lucia, D.; De Francesco, F.; Marotta, R.; Maisto, G.; Meo, D.; Sessa, M.; Misso, M.; Galante, M.; Russo, T.; Pignalosa,O.; Napolitano, M.; Papa, M.L.; Niglio, A.; Di Micco, P. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma. Exp Oncol 2005, 27, 159-161.
67. Sase, T.; Wada, H.; Yamaguchi, M.; Ogawa, S.; Kamikura, Y.; Nishikawa, M.; Kaneko, T.; Abe, Y.; Nishioka, J.; Nobori, T.; Shiku, H. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005, 93, 153-159.
68. Minnema, M.C.; Fijnheer, R.; De Groot, P.G.; Lokhorst, H.M. Extremely high levels of vonWillebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003, 1, 445-449.
69. Hugo, J.Z.; Jeanet, D.M. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006, 21, 4-11.
70. Elice, F.; Fink, L.; Tricot, G.; Barlogie, B.; Zangari, M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006, 134, 399-405.
71. van Marion, A.M.; Auwerda, J.J.; Minnema, M.C.; van Oosterom, R.; Adelmeijer, J.; de Groot, P.G.; Leebeek, F.W.; Sonneveld, P.; Lokhorst, H.M.; Lisman, T. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005, 94, 1341-1343.
72. Leone, G.; Gugliotta, L.; Mazzucconi, M.G.; De Stefano, V.; Belmonte, M.M.; Dragoni, F.; Specchia, G.; Centra, A.; Gamba, G.; Camera, A.; et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-Asparaginase: a GIMEMA study. Thromb Haemost 1993, 69, 12-15.
73. Warrell, R.P.; de The, H.; Wang, Z.Y.; Degos, L. Acute promyelocytic leukemia. N Engl J Med 1993, 329, 177-189.
74. Castaigne, S.; Chomienne, C.; Daniel, M.T.; Ballerini P.; Berger, R.; Fenaux, P.; Degos, L. All-trans retinoic acid as a differentation therapy for acute promyelocytic leukemia. Blood 1990, 76, 1704-1709.
75. Falanga, A.; Iacoviello, L.; Evangelista, V.; Belotti, D.; Consonni, R.; D'Orazio, A.; Robba, L.; Donati, MB.; Barbui, T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocitic leukemia given all-trans-retinoic acid. Blood 1995, 86, 1072-1084.
76. Tallman, M.S.; Lefèbvre, P.; Baine, R.M.; Shoji, M.; Cohen, I.; Green, D.; Kwaan, H.C.; Paietta, E.; Rickles, F.R. Effects of alltrans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocitic leukemia. J Thromb Haemost 2004, 2, 1341-1350.
77. Dombret, H.; Scrobohaci, M.L.; Daniel, M.T.; Micĺea, J.M.; Castaigne, S.; Chomienne, C.; Fenaux, P.; Degos, L. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995, 9, 19-24.
78. Lee, A.Y.; Levine, M.N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999, 25, 137-145.
79. Zangari, M.; Saghafifar, F.; Mehta, P.; Barlogie, B.; Fink, L.; Tricot, G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003, 29, 275-282.
80. Wang, M.; Weber, D.M.; Delasalle, K.; Alexanian, R. Thalidomidedexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005, 79, 194-197.
81. Palumbo, A.; Bringhen, S.; Caravita, T.; Merla, E.; Capparella, V.; Callea, V.; Cangialosi, C.; Grasso, M.; Rossini, F.; Galli, M.; Catalano, L.; Zamagni, E.; Petrucci, M.T.; De Stefano, V.; Ceccarelli, M.; Ambrosini, M.T.; Avonto, I.; Falco, P.; Ciccone, G.; Liberati, A.M.; Musto, P.; Boccadoro, M.; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367, 825-831.
82. Minnema, M.C.; Breitkreutz, I.; Auwerda, J.J.; van der Holt, B.; Cremer, F.W.; van Marion, A.M.; Westveer, P.H.; Sonneveld, P.; Goldschmidt, H.; Lokhorst, H.M. Prevention of venous thromboembolism with low molecular-weight hepatin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004, 18, 2044-2046.
83. Offidani, M.; Corvatta, L.; Piersantelli, MN.; Visani, G.; Alesiani, F.; Brunori, M.; Galieni, P.; Catarini, M.; Burattini, M.; Centurioni, R.; Ferranti, M.; Rupoli, S.; Scortechini, A.R.; Giuliodori, L.; Candela, M.; Capelli, D.; Montanari, M.; Olivieri, A.; Poloni, A.; Polloni, C.; Marconi, M.; Leoni, P. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006, 108, 2159-2164.
84. Zangari, M.; Barlogie, B.; Anaissie, E.; Saghafifar, F.; Eddlemon, P.; Jacobson, J.; Lee, C.K.; Thertulien, R.; Talamo, G.; Thomas, T.; Van Rhee, F.; Fassas, A.; Fink, L.; Tricot, G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126, 715-721.
85. Lyman, G.H.; Khorana, A.A.; Falanga, A.; Clarke-Pearson, D.; Flowers, C.; Jahanzeb, M.; Kakkar, A.; Kuderer, N.M.; Levine, M.N.; Liebman, H.; Mendelson, D.; Raskob, G.; Somerfield, M.R.; Thodiyil, P.; Trent, D.; Francis, C.W.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25, 5490-5505.
86. Lee, A.Y.Y.; Levine, M.N.; Baker, R.I.; Bowden, C.; Kakkar, A.K.; Prins, M.; Rickles, F.R.; Julian, J.A.; Haley, S.; Kovacs, M.J.; Gent, M.; Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349, 146-153.